Current and Future Trials of the EORTC Brain Tumor Group

Bent, Martin J. van den; Stupp, Roger; Brandes, Alba A.; Lacombe, Denis

doi:10.1159/000077974

Cited by 18 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This lack of an apparent advantage for dose increments of only 10 Gy might be due to the flat slope of the dose-effect curve in this range. Novel chemotherapeutic agents are going to be investigated in multiple phase II and III studies of the EORTC [20]. In particular, temozolomide in addition to radiotherapy can improve the outcome [21].…”

Section: Discussionmentioning

confidence: 99%

Dose-Escalated Conformal Radiotherapy of Glioblastomas – Results of a Retrospective Comparison Applying Radiation Doses of 60 and 70 Gy

Graf¹,

Hildebrandt²,

Tilly³

et al. 2005

Oncol Res Treat

View full text Add to dashboard Cite

Background: Dose escalated three-dimensional conformal radiotherapy with 70 Gy against glioblastomas was compared retrospectively with the standard scheme of 60 Gy using 2-D-planning. Patients and Methods: In the period from 1994 to 1998, a series of 135 patients with glioblastomas was treated by surgery and postoperative radiotherapy. A conversion from 2-D into 3-D-planning was carried out in 4/1996. The prescribed total dose for the first 65 patients was 60 Gy (group 60). A boost up to 70 Gy was added for the remaining 70 patients (group 70). Results: The median survival time was 8.0 months for group 60 and 8.3 months for group 70. A dependency on the applied dose range was found. The median survival time was 3 months for patients who received a radiation dose of 55 Gy or less, 8.6 months for doses between 56 and 65 Gy, and 9.6 months for patients with a dose between 66 and 75 Gy (p < 0.01). In a multivariate analysis only the performance status maintained significance (p = 0.02) as a prognostic factor, while the dose range reached borderline significance (p = 0.09). Conclusion: No statistically significant survival prolongation was reached despite a dose escalation to 70 Gy.

show abstract

Section: Discussionmentioning

confidence: 99%

Dose-Escalated Conformal Radiotherapy of Glioblastomas – Results of a Retrospective Comparison Applying Radiation Doses of 60 and 70 Gy

Graf¹,

Hildebrandt²,

Tilly³

et al. 2005

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…The extent of resection and the interval between surgery and radiotherapy were also prognostic factors of MB (12,13). Chemotherapy has been administered for the treatment of MB for >20 years; initially, the regimens were the same as those used to treat childhood MB, however, temozolomide has begun to replace older chemotherapeutic combinations with a reasonable efficacy and decreased adverse effects (7,14). The clinical presentation and imaging features of the disease are different in adults compared with children with MB, and have the following characteristics: i) The craniosynostosis of adults has closed and thus the compensatory ability of the cranial space is poor.…”

Section: A B C Dmentioning

confidence: 99%

“…It is generally believed that the overwhelming majority of cases reported with extraneural metastasis occur in patients who underwent a craniotomy (6). At present, typical treatments for high-risk childhood MB include maximal surgery, craniospinal radiation therapy and adjuvant chemotherapy (7)(8)(9). The 2-and 5-year overall survival rates following diagnosis of extraneural metastasis have been reported to be 31 and 26%, respectively (10).…”

Section: Introductionmentioning

confidence: 99%

Medulloblastoma with soft-tissue and skeletal metastases in an adult: A case report

et al. 2015

View full text Add to dashboard Cite

Abstract. Medulloblastoma (MB) is a highly malignant primary brain tumor, which occurs in the cerebellum or posterior cranial fossa. MB is most commonly identified in children <10 years of age. The disease is rare in adults, affecting patients aged between 30 and 50 years of age, with an incidence of 0.5 cases per 1,000,000 individuals. Extraneural metastases are reported in 7-10% of cases, most commonly involving the bones and more rarely involving the lymph nodes, visceral organs and bone marrow. The current study presents the case of a 36-year-old male who underwent a gross total resection followed by radiation therapy to the craniospinal axis for the treatment of MB. The patient subsequently developed widespread metastasis, which involved the soft tissue of the occipital bone. Subsequently, the patient was administered palliative radiotherapy and initially exhibited a good clinical response. However, the patient succumbed at 18 months post-diagnosis due to dissemination of the disease. The literature on the extraneural metastasis of MB is also reviewed in the current study. IntroductionMedulloblastoma (MB) is the most common primary brain tumor in children; however, the malignancy rarely occurs in adults (1). In total, 7-10% of patients diagnosed with MB develop extraneural metastases, which most commonly involve the bone and lymph nodes, and recently, the frequency of reported extraneural metastases has increased (2-4). The visceral organs are less common sites of extraneural spread in medulloblastoma (5). It is generally believed that the overwhelming majority of cases reported with extraneural metastasis occur in patients who underwent a craniotomy (6). At present, typical treatments for high-risk childhood MB include maximal surgery, craniospinal radiation therapy and adjuvant chemotherapy (7-9). The 2-and 5-year overall survival rates following diagnosis of extraneural metastasis have been reported to be 31 and 26%, respectively (10). In general, the survival rate is considered to be poor. In the current study, the case of a 36-year-old male MB patient with recurrent disease involving the soft tissues of the occipital bone is presented, as well as the subsequent treatment course of the patient. In addition, the extraneural metastasis of MB is discussed. Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. Case reportOn November 15, 2009, a 36-year-old male presented at the Binzhou Medical University Hospital (Binzhou, China) with nausea and vomiting that had persisted for 5 days, but was not accompanied by headache, visual impairment or ataxia. The patient had no significant previous medical history. Cranial magnetic resonance imaging (MRI) revealed the presence of a lesion in the fourth ventricle. Total spinal MRI revealed no evidence of additional central nervous system disease. Subsequently, three days after presentation, the patient underwent a posterior fossa craniotomy with gross total resection of the tumor, in which the cereb...

show abstract

“…eortc.be) is conducting phase II and phase III studies in brain tumors, brain metastasis and primary cerebral lymphomas [3]. An important future aspect are translational studies, focusing on genetic aspects of tumors.…”

Section: What Is the Scope Of Neurooncology?mentioning

confidence: 99%

“…In adult neurooncology some progress has been made in the treatment of oligodendroglioma, whereas treatment of glioblastoma, the most frequent adult tumor, still remains unsatisfactory. This issue of ONKOLOGIE contains four articles selected out of the broad spectrum of neuroncology focused on pediatric neurooncology [2], primary brain tumors in adulthood [3], brain edema [4] and paraneoplastic disease [5]. Brain tumors are the most frequent tumor entity in children.…”

mentioning

confidence: 99%

Neurooncology – Present and Future

Grisold¹

2004

Oncol Res Treat

View full text Add to dashboard Cite

Current and Future Trials of the EORTC Brain Tumor Group

Cited by 18 publications

References 24 publications

Dose-Escalated Conformal Radiotherapy of Glioblastomas – Results of a Retrospective Comparison Applying Radiation Doses of 60 and 70 Gy

Dose-Escalated Conformal Radiotherapy of Glioblastomas – Results of a Retrospective Comparison Applying Radiation Doses of 60 and 70 Gy

Medulloblastoma with soft-tissue and skeletal metastases in an adult: A case report

Neurooncology – Present and Future

Contact Info

Product

Resources

About